Kymera Therapeutics Presents Promising Preclinical Data for KT-621, a First-in-Class Oral STAT6 Degrader, Demonstrating Comparable Efficacy to Dupilumab in Chronic Asthma Model
19/5 18:20
Kymera Therapeutics disclosed positive preclinical data for KT-621, an oral STAT6 degrader, showing potential for asthma and dermatitis treatment....